Barrett R. Harvey, Ph.D.
Assistant Professor
Center for Immunology & Autoimmune Diseases
Program in Applied Biologics
phone 713.500.3485;
fax 713.500.2420
Barrett.Harvey@uth.tmc.edu
Dr. Barrett Harvey earned his Ph.D. from the University of Texas at Austin in 2003. He joined Merck Research Laboratories in 2004 as a Senior Research Scientist in the Department of Vaccines and Biologics. In 2007 he was recruited by the Institute of Molecular Medicine at the University of Texas Health Science Center at Houston and appointed Assistant Professor of Molecular Medicine. His current research interests focus on design and development of recombinant antibodies and biologics as they relate to therapeutic, diagnostic and basic research needs. To this end, the laboratory ventures into a number of diverse biological fields including oncology, cardiology, neurology, and infectious disease.
Utilizing high throughput strategies the lab investigates the design of new technology for the discovery of novel therapeutic targets, maturation of antibody fragments, and for efficient antibody generation.
In addition the lab explores specific features of antibodies that make them best suited for individual applications including isotype, affinity, epitope, half-life, stability and valency.
Specific research programs include the evaluation of passive immunization strategies against gram positive pathogens, the design of mouse models to examine the potency of directed cancer therapies, and the exploration of potential cardiac risk candidates as targets for recombinant antibody therapy.
Publications and Patents
Automated High-Throughput Purification of Antibody Fragments to Facilitate Evaluation in Functional and Kinetic Based Assays. Su B, Hrin R, Harvey BR, Yang Y, Ernst RE, Hampton RA, Miller MD, Strohl WR, An Z, Montgomery DL. Journal of Immunological Methods. 7 March (2007)
Engineering of Recombinant Antibody Fragments by Anchored Periplasmic Expression (APEx). Harvey BR, Shanafelt A, Baburina I, Hui R, Vitone S, Iverson BL, Georgiou G. Journal of Immunological Methods, Jan 20; 308(1-2): 43-52 (2006)
Flow Cytometry for Biotechnology Chapter 12 “Applications of Flow Cytometry in Protein Engineering” George Georgiou, Barrett R. Harvey, Karl E. Griswold, Brent L. Iverson. Edited by Larry A. Sklar, Oxford University (2005)
Selection of Bacterial Inner-Membrane Anchor Polypeptides. U.S. Patent 20050260736 – Georgiou G, KI JJ, Harvey BR, Iverson BL. (2005)
Human Antibody against Shiga Toxin 2 Administered to Piglets after the Onset of Diarrhea Due to Escherichia coli O157:H7 Prevents Fatal Systemic Complications. Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S. Infection and Immunity 73(8) 4607-4613. (2005)
Anchored Periplasmic Expression (APEx), a Versatile Technology for the Isolation of High Affinity Antibodies from E.coli Expressed Libraries. Harvey BR, Georgiou G, Hayhurst A, Iverson BL, Rogers GK. Proc Natl Acad Sci U S A. Jun 22;101(25):9193-9198. (2004)
A Periplasmic Fluorescent Reporter Protein and its Application in High-Throughput Membrane Protein Topology Analysis. Ki JJ, Kawarasaki Y, Gam JS, Harvey BR, Iverson BL, Georgiou G. Journal of Molecular Biology 341(4), 901-909 (2004)
Antibodies with Increased Affinities for Anthrax Antigens U.S. Patent 20050106647 –Harvey BR, Georgiou G, Iverson BL. (2003)
Combinatorial Protein Library Screening By Anchored Periplasmic Expression U.S. Patent 20040058403 - Harvey BR, Georgiou G, Iverson BL. (2002)
Isolation of High-Affinity Ligand-Binding Proteins by Periplasmic Expression with Cytometric Screening (PECS) Chen G, Hayhurst A, Thomas JG, Harvey BR, Iverson BL, Georgiou G. Nature Biotechnology 19, 537-542 (2001)